Valens GroWorks Corp (CSE:VGW, OTC:VGWCF) has sponsored the “The Future of Cannabis in Canada” report by Resonance Consultancy, in partnership with Insights West. Valens is a vertically-integrated provider of cannabis products for the global cannabis nutraceuticals market. The report covers cannabis consumption demands and trends in Canada since legalization in 2018.

“At Valens, we have a unique position in this growing cannabis market as a supply-chain partner and a co-packer of consumer goods for licensed producers across the country. We have a responsibility to help guide trends and provide quality products,” said Valens Executive VP of Strategy and Investments Everett Knight


In total, Valens and Resonance Consultancy surveyed 1,500 Canadians who had used cannabis in the past year, while Insights West surveyed 1,001 legal adults throughout Canada to give a broad view of the public’s perception of the plant. The report covers topics such as consumer demographics, consumption data, cannabis marketing campaigns, canna-tourism, sales and distribution among others.

Most importantly, the report also covers future trends for the market. Resonance Consultancy believes that cannabis will be in everything as cannabis companies and the Canadian government figure out what consumers want and what will be allowed to go to market over the next few years. Luxury cannabis brands will be a predominant trend moving forward, and women’s involvement in the industry will grow as they create cannabis lines and brands for other women.

“This report summarizes what it’s like living in Canada with legal cannabis, both through the eyes of a bystander and a consumer. As an emerging industry, breaking down consumer needs and desires has never been more necessary to sustain long-term market growth,” said Knight.

To read the full report, click here.

infoClick here to connect with Valens GroWorks Corp (CSE:VGW, OTC:VGWCF)  for an Investor Presentation. 

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less